Abstract:Objective: To compare the differences in the clinicopathological and molecular biological features between the breast cancer patients with estrogen receptor (ER) + /progesterone receptor (PR) + or ER + /PR - tumors. Methods: The clinicopathological data of 3124 female breast cancer patients with known ER/PR expression status, 2220 being ER + /PR + and 904 being ER + /PR -, and 1484 being ER - /PR -, were analyzed retrospectively. Immunohistochemistry was used to detect the expression of c-erb and cathapsin D in the tumor specimens. Results: The average peak onset age was 50 years in both the ER + /PR + and ER + PR- patients, and the mean age of the ER + /PR + patients was 52.40 years, not significantly different from that of the ER - /PR - patients (52.57 years, P = 0.709). The peak onset age of the ER + patients was 50 years, significantly higher that that of the ER - patients (48 years, P = 0.001), and the mean age of the ER + patients was 52.46 years, significantly higher than that of the ER - patients (51.42 years, P = 0.001). Univariate analysis showed that ER + /PR - tumors tended to be larger. 24.8% of the ER + /PR- patients had 4 or more metastatic lymph nodes, a rate significantly higher than that of the ER + /PR - patients (20.7%, P = 0.004). The tumors of 18% of the ER + /PR - patients were at the grade III, a rate significantly higher than that of the ER + /PR + patients (13.5%, P = 0.008). The strong positivity rate of the ER + /PR + tumors was 23.4%, ignorantly higher than hat of the ER + /PR - tumors (11.2%, P = 0.000). The c-erB-2 positive rate of the ER + /PR + tumors was 19.7%, significantly lower than that of the ER + /PR - tumor group (28.7%, P = 0.000). The cathepsin D positive rate of the ER + /PR - group was 76.9%, significantly higher than that of the ER + /PR- group (71.9%, P = 0.005). Multivariate analysis indicated that positive PR expression was associated with the level of ER (OR = 1.792,95% CI = 1.484-2.164, P = 0.000), cathepsin D(OR = 1.380,95% CI = 1.023 - 1.862,P = 0.035) and c-erbB-2(OR = 0.639,95% CI = 0.463 - 0.883,P = 0.007). Conclusion: ER + /PR + and ER + /PR - tumors may have identical etiology. The mechanism of whether PR is expressed in ER + breast cancer may be caused by different factors, which causing many different aspects. According to these differences, new target of therapy may provide the possibility of improving the response and prognosis for patients with ER + /PR - tumors.

A Comparison Of Tumor Characteristics Between Er Plus /Pr Plus And Er Plus /Pr- Breast Tumors In Chinese Women

EFFECT OF ADJUVANT ENDOCRINE THERAPY ON ESTROGEN RECEPTOR-NEGATIVE, PROGESTERONE RECEPTOR-POSITIVE AND HER2 NEGATIVE BREAST CANCER PATIENTS

Clinico-pathological features of ER+/PR+ and ER+/PR-breast tumors:a comparative study of 5211 cases

Analysis of the Clinicopathologic Characteristics and Prognosis of Breast Cancer Patients with ER or PR Single-positive Status

Clinical Features and Prognosis Analysis of Hormone Receptor-Positive, HER2-Negative Breast Cancer with Differential Expression Levels of Estrogen and Progesterone Receptors: A 10-Year Retrospective Study

Prognostic Impact of Progesterone Receptor Status in Chinese Estrogen Receptor Positive Invasive Breast Cancer Patients

Distinct ER and PR expression patterns significantly affect the clinical outcomes of early HER2-positive breast cancer: A real-world analysis of 871 patients treated with neoadjuvant therapy

Combined Estrogen Receptor and Progesterone Receptor Level Can Predict Survival Outcome in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer

The Efficacy of Adjuvant Endocrine Therapy for ER(-)PR(+) Primary Breast Cancer

The Diverse Distribution Of Risk Factors Between Breast Cancer Subtypes Of Er, Pr And Her2: A 10-Year Retrospective Multi-Center Study In China

Expressions of Progesterone Receptor a and B in Breast Invasive Ductal Carcinoma and Their Clinical Significance

Clinical Outcomes and Intrinsic Subtypes of Breast Cancer Patients with Single Hormone Receptor-positive Receiving Neoadjuvant Chemotherapy

Expressions of c-erbB-2, ER, PR and their prognostic correlation in premenopausal and postmenopausal patients with breast cancer.

Correlation of Hormone Receptors Expression and Response to Neoadjuvant Chemotherapy in Breast Cancer

Clinical Characteristics and Disease Outcomes in ER+ Breast Cancer: a Comparison Between HER2+ Patients Treated with Trastuzumab and HER2- Patients.

Clinical Research on ER, PR Status with Recurrence and Distant Metastatic Site in Primary Breast Cancer

Are Single Hormone Receptor-Positive Phenotypes Biologically and Clinically Distinct Breast Cancer? A Population-Based Study.

Clinical Pathologic Status and Expression of Tumor Markers in 5,000 Chinese Breast Cancers

Clinicopathological differences and survival benefit in ER+/PR+/HER2+ vs ER+/PR−/HER2+ breast cancer subtypes

Breast Cancer Subtypes and Survival in Chinese Women with Operable Primary Breast Cancer

Comparison of ER/PR and HER2 statuses in primary and paired liver metastatic sites of breast carcinoma in patients with or without treatment